Video

Dr. Mileham Discusses Biomarkers in Lung Cancer

Kathryn Mileham, MD, medical oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses biomarkers in lung cancer.

Kathryn Mileham, MD, medical oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses biomarkers in lung cancer.

The landscape of lung cancer has changed tremendously over the past 20 years, says Mileham. With the discovery of numerous mutations, the development of biomarkers and biomarker testing has blossomed.

Mileham says that the established biomarkers that are predictive in response for non—small cell lung cancer are ALK, ROS1, EGFR, BRAF, and PD-L1.

Related Videos
Matthew P. Deek, MD
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
Guru P. Sonpavde, MD
David Rimm, MD, PhD
Suneel Kamath, MD
Kathleen N. Moore, MD, MS
Shaji Kumar, MD
Janaki Neela Sharma, MD
Karine Tawagi, MD,
Vered Stearns, MD